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The development of safe and efficacious immunization systems to prevent brucellosis is needed to overcome the
disadvantages of the currently licensed vaccine strains that restrict their use in humans. Alginate microspheres
coated with a protein of the parasite Fasciola hepatica (vitelline protein B [VpB]) and containing live Brucella
melitensis attenuated mutant vjbR::Tn5 (BMEII1116) were evaluated for vaccine efficacy and immunogenicity in
mice. A single immunization dose in BALB/c mice with the encapsulated vjbR mutant improved protection against
wild-type B. melitensis 16M challenge compared to the nonencapsulated vaccine strain (P< 0.05). The encapsulated
mutant was also shown to induce a sustained elevation of Immunoglobulin G levels. Cytokine secretion from spleen
cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed elevated secretion of gamma interferon and
interleukin-12, but no interleukin-4, suggesting an induction of a T helper 1 response reflecting the enhanced
immunity associated with microencapsulation. Together, these results suggest that microencapsulation of live
attenuated organisms offers the ability to increase the efficacy of vaccine candidates.
Brucella, an obligate intracellular bacterium, is the causative
agent of brucellosis, a zoonosis of nearly worldwide distribu-
tion (8). Among the six different Brucella species, Brucella
melitensis, B. suis, and B. abortus are pathogenic and virulent
not only for sheep, goats, swine, and cattle, respectively, but
also for humans. Despite the availability of live vaccine strains
for cattle (S19 and RB51) and small ruminants (Rev-1), these
vaccines have several drawbacks, including interference with
diagnosis, resistance to antibiotics, and residual virulence, that
prevent the use of these vaccines in humans (4, 6, 28). Numer-
ous attempts to develop safe and more effective vaccines, in-
cluding the use of killed organisms, cell extracts, or recombi-
nant proteins, has had limited success (18, 22, 27, 28, 33).
In the absence of defined protective immunogens, the use of
attenuated vaccine strains offers the best approach. As an
alternative, we have investigated the ability to combine an
attenuated live vaccine delivered in a controlled release vehi-
cle. For this purpose, alginate, a naturally occurring biopoly-
mer, offers advantages, including biocompatibility and rela-
tively mild conditions required to produce an alginate matrix
or particle (7). Extensive investigation has shown the efficacy of
this release system when used to encapsulate protein agents
such as insulin, erythropoietins, and chemokines (20, 25, 32).
To further increase the efficacy of the capsular delivery, a novel
recombinant form of the vitelline protein B (VpB) derived
from the eggshell precursor of the parasite Fasciola hepatica
was incorporated into the capsules (26). VpB possesses an
unusual resistance to enzymatic and chemical breakdown that
is expected to extend the time frame of erosion and release of
the capsule content (34).
Ongoing research in our laboratory has identified B. meliten-
sis genes required for virulence and survival via transposon
mutagenesis (3, 16). Among these, vjbR (BMEII1116), encod-
ing the luxR-like quorum-sensing-related transcriptional regu-
lator, is required for adequate virB expression (10). Although
virB expression is diminished in the vjbR mutant, it is not
completely abrogated (T. A. Ficht et al., unpublished results).
The vjbR mutants of B. melitensis are highly attenuated in mice
and macrophages, making such mutants ideal vaccine candi-
dates. Due to their attenuation and rapid clearance from the
host, the utility of encapsulation of the vjbR mutant into alg-
inate/VpB microcapsules was examined with the aim of pro-
ducing enhanced immunization systems that are safe and more
efficacious for human use.
In the present study, we demonstrate the efficacy of using
controlled release systems with live attenuated B. melitensis
vjbR::Tn5 mutant as a vaccine candidate against subsequent B.
melitensis exposure. Vaccination with the encapsulated mutant
induced a robust and sustained cellular and humoral response
that correlated with higher levels of protection compared to
the nonencapsulated vaccine. Furthermore, the protective ef-
ficacy of the vaccines correlated with a specific improvement in
T helper 1 (Th1) response.
MATERIALS AND METHODS
Mice. A total of 120 4- to 6-week-old female BALB/c mice were obtained from
the Jackson Laboratory (Bar Harbor, ME) and acclimated for 2 weeks. All
experimental procedures and animal care were performed in compliance with
institutional animal care regulations.
Bacterial strains. The bacterial strains used in these experiments include B.
melitensis vjbR::Tn5 as the vaccine candidate and the B. melitensis virulent strain
16M. For assessment of bacterial incorporation inside the capsule, 16M trans-
formed with the pBBR1mcs 6-y plasmid and expressing the reporter protein
green fluorescent protein (GFP) was kindly provided by R. Martin Roop II.
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Bacteria were grown on tryptic soy agar (TSA) at 37°C with 5% (vol/vol) CO2.
For vjbR::Tn5, the medium was supplemented with kanamycin (100 g/ml).
After 3 days of incubation, bacteria were harvested from the surface of plates
into phosphate-buffered saline. The bacteria were pelleted, washed twice by
resuspension in buffer containing morpholinepropanesulfonic acid (MOPS; 10
mM MOPS, 0.85% NaCl [pH 7.4]), and resuspended to a final concentration of
2  106 CFU/ml based upon optical density readings obtained using a Klett
meter and a standardized curve. The actual viable counts were confirmed by
serial dilution and plating of portions onto TSA plates with or without antibiotic.
Evaluation of B. melitensis vjbR::Tn5 in J774A.1 macrophages. Murine mac-
rophage-like J774.A1 (ATCC TIB-67) were used to assess vjbR::Tn5 mutant
survival compared to the parental B. melitensis wild-type 16M. Macrophage
survival assays were performed as previously described, with some modifications
(24). Briefly, macrophages were cultured in Dulbecco modified Eagle medium
with 10% (vol/vol) fetal bovine serum, 1 mM L-glutamine, and 1 mM nonessen-
tial amino acids. Monolayers of macrophages containing 2.5  105 cells per well
were infected at a multiplicity of infection of 1:100 at 37°C with either vjbR::Tn5
or wild-type 16M. At 30 min postinfection, the cells were washed twice with
medium without antibiotics and then incubated with 50 g of gentamicin (In-
vitrogen)/ml for 30 min to kill any extracellular bacteria. At 1 and 48 h postin-
fection, macrophages were lysed with 0.05% (vol/vol) Tween 20, and the bacteria
were collected. Brucella entry and survival was determined by performing serial
dilutions and plating onto TSA plates with or without antibiotic. All assays were
performed in triplicate and repeated at least three times.
Evaluation of B. melitensis vjbR::Tn5 attenuation in mice. Female BALB/c
mice were used to evaluate the survival of the vjbR::Tn5 mutant. Briefly, 6- to
8-week-old mice were intraperitoneally inoculated with a total of 2  106 CFU
of either mutant or wild-type organism. Groups of five mice were euthanized via
carbon dioxide asphyxiation at 1, 2, 3, and 4 weeks postinoculation. At each time
point, spleens were collected, weighed, and homogenized in 1 ml of peptone
saline. Serial dilutions were prepared, and 100-l aliquots of the different dilu-
tions were plated in duplicate onto TSA or TSA-kanamycin. Levels of infection
were expressed as the mean  the standard error of the mean (SEM) of the
individual log CFU/spleen.
Preparation of B.melitensis antigen-loaded microspheres. Alginate beads were
prepared as previously described with some modifications(1). Briefly, 6  106
CFU of the live B. melitensis mutant vjbR::Tn5 were resuspended in 1 ml of
MOPS buffer (10 mM MOPS, 0.85% NaCl [pH 7.4]) and mixed with 5 ml of
alginate solution (1.5% sodium alginate, 10 mM MOPS, 0.85% NaCl [pH 7.3]).
Spheres were obtained by extruding the suspension through a 200-m nozzle into
a 100 mM calcium chloride solution and stirred for 15 min by using an Inotech
Encapsulator I-50 (Inotech Biosystems International, Rockville, MD). After
extrusion of the bacterium-alginate mixture into the CaCl2, the capsules were
washed twice with MOPS for 5 min and further cross-linked with 0.05% poly-L-
lysine (molecular weight. 22,000; Sigma) for 10 min. After two successive washes,
the beads were stirred in a solution of 0.03% (wt/vol) alginate for 5 min to apply
a final outer shell and washed twice with MOPS before storage at 4°C.
In a second formulation, VpB was added as a component of the alginate core
(vjbR::Tn5/VpB/core) by the addition of 1 mg of VpB to the bacterium-alginate
suspension described above. Extrusion and capsule formation used the same
preparation conditions.
VpB was alternatively added to the shell of the capsule (vjbR::Tn5/VpB/shell)
as a cross-linking agent by the addition of VpB in an equimolar ratio of poly-L-
lysine/VpB as the third capsule formulation used.
Bacterial viability. To determine the bacterial content per milliliter of alginate
particles, 1 ml of capsules was removed from the encapsulator prior to perma-
nent cross-linking with poly-L-lysine or cross-linking with VpB plus poly-L-lysine.
The capsules were allowed to settle and washed twice with MOPS buffer, and
particles were dissolved by using 1 ml of depolymerization solution (50 mM
sodium citrate, 0.45% NaCl, 10 mM MOPS [pH 7.2]) with stirring for 10 min.
Bacterial numbers (in CFU/ml) of capsules were determined by plating onto
TSA plates.
Characterization of microspheres. The bacterial presence inside the capsule,
the sphere morphology, and the size were assessed via fluorescence microscopy
(Nikon, TMS). Three size determinations were made for each formulation, and
the mean values were reported.
In vitro bacterial release from the capsules. Bacterial release from the cap-
sules was assessed by using 1 ml of capsules containing 109 CFU resuspended in
10 ml of peptone saline (pH 7.2). The release study was conducted for 37 days.
At 24-h intervals, 1 ml of peptone saline was removed and plated onto TSA to
determine bacterial release from the capsule. The buffer was replaced completely
after the withdrawal of each aliquot. Nonencapsulated bacteria were used as a
control and subjected to the same procedure. Release profiles were expressed in
terms of daily release and plotted versus time. All measurements were performed
in triplicate, and the experiment was repeated three times.
Kinetics of bacterial clearance from mice vaccinated with encapsulated vjbR::
Tn5. To further understand the kinetics of bacterial release from alginate mi-
crospheres in vivo, BALB/c mice were vaccinated with either encapsulated or
nonencapsulated vjbR::Tn5 strain at a dose of 105 CFU. Mice were euthanized at
1, 2, 3, 4, 5, 6, and 7 weeks postinoculation, and the spleens were harvested,
weighed, and homogenized in 1 ml of peptone saline. Bacterial suspensions were
serially diluted, and 200 l of the homogenate was plated onto TSA-kanamycin
plates. In some instances the whole homogenate was plated to increase the limit
of detection to one organism. Bacterial release from the beads was indirectly
measured by determination of the CFU encountered in the spleen.
Immunization of mice. Sixty 6- to 8-week-old female BALB/c mice were
randomly divided into groups of 10 for intraperitoneal vaccination. Animals were
given a single dose of microcapsules containing 105 CFU of either (i) encapsu-
lated B. melitensis mutant vjbR::Tn5 in alginate (vjbR::Tn5/alginate), (ii) encap-
sulated vjbR::Tn5 mutant in alginate with VpB inside the capsule (vjbR::Tn5/
VpB/core), or (iii) encapsulated vjbR::Tn5 mutant in alginate with VpB in the
shell of the sphere (vjbR::Tn5/VpB/shell). Control groups received 105 CFU of
either (i) nonencapsulated vjbR::Tn5 mutant, (ii) empty capsules (no bacteria
entrapped), or (iii) 200 l of MOPS buffer.
Evaluation of Brucella-specific antibody. To determine anti-Brucella-specific
antibody in sera from inoculated mice, 100 l of blood was taken from each
mouse 0, 2, 4, 8, 10, 12, 14, 18, 24, and 30 weeks postvaccination and used for
immunoglobulin G (IgG) determination by enzyme-linked immunosorbent assay
(ELISA). Heat-killed and sonicated B. melitensis whole-cell antigen was used to
coat 96-well plates (Nunc-Immuno plates) at a concentration of 25 g of total
protein/well. After overnight incubation at 4°C, plates were washed, blocked with
0.5 ml of blocking buffer (0.25% [wt/vol] bovine serum albumin), and then
incubated with mouse sera diluted 1:100 in the same blocking buffer for 1 h at
room temperature. After extensive washing to remove unbound antibody, rabbit
anti-mouse IgG-horseradish peroxidase conjugate (KPL) was added at a dilution
of 1:1,000, and incubation continued for an additional hour. After this incubation
the plates were washed again, and horseradish peroxidase substrate was added,
followed by incubation for 18 min. The reaction was stopped by the addition of
50 l of 0.5 M NaOH, and the absorbance was measured at 450 nm (A450). All
assays were performed in triplicate and repeated at least three times. For IgG
isotype and recall determination, serum samples at the day of challenge and 3
days postchallenge were diluted (1:100 to 1:100,000). Endpoint titers were ex-
pressed as the maximum dilution of sample above three standard deviations from
the control sera. The results are represented as the mean of triplicate wells for
each sample.
Determination of splenocyte cytokine production. At selected times postvac-
cination, individual spleens from five animals per group were extracted, and
single-cell suspensions were obtained by homogenizing the spleen using glass
tissue grinders. After lysis of erythrocytes using red blood cell lysing buffer (8.3
g of NH4Cl in 0.01 M Tris-HCl [pH 7.5]), the cell suspension was washed in
complete RPMI 1640 medium containing 10% (vol/vol) fetal bovine serum and
50 g of gentamicin/ml. The cell number was adjusted, and cells were added to
24-well plates at a concentration of 2.5 105 cells/well and cultured following the
addition of 25 g of B. melitensis lysate/well prepared as described above. Cells
in control wells received medium alone. At 72 h after incubation at 37°C in 5%
(vol/vol) CO2, culture supernatants were collected and stored at 20°C. Inter-
leukin 4 (IL-4), IL-12p70, and gamma interferon (IFN-) cytokines were deter-
mined in triplicate by using a Bioplex array system (Bio-Rad) according to the
manufacturer’s instructions. For each cytokine, eight standards ranging from 2 to
32,000 pg/ml were quantitated.
Determination of cytokine production in vivo. At 0, 10, and 30 weeks post-
vaccination, animals were bled and serum was obtained from each individual
mouse for cytokine determination. Quantification of IFN- and IL-12p70 was
determined by ELISA (Ebioscience) according to the manufacturer’s instruc-
tions. All samples were performed in triplicate, and the assay was repeated three
times. For each cytokine, standards ranging from 0.2 to 1,000 pg/ml were quan-
titated. Background levels obtained for t  0 were subtracted from the samples.
The differences between the encapsulated and nonencapsulated formulations at
each time point were determined by analysis of variance (ANOVA). The results
are represented as the mean picograms of each cytokine/ml  the standard
deviation.
Efficacy of vaccination. At selected times postvaccination, mice (n  five
animals per group) were challenged interperitoneally with 105 CFU of B. meliten-
sis wild-type 16M/mouse. At 1 week postchallenge, mice were euthanized by CO2
asphyxiation, and the spleens were removed, weighed, and homogenized in 1 ml
of peptone saline. Serial dilutions were prepared, and 100-l portions were
VOL. 76, 2008 IMMUNIZATION WITH B. MELITENSIS MUTANT 2449
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
plated onto TSA plates. In some instances, 200 to 1,000 l of spleen homogenate
was plated to determine organism recovery. To differentiate between the vaccine
candidate and the challenge strain, each dilution was also plated on TSA with
kanamycin to identify any residual kanamycin-resistant vaccine strain present.
Levels of infection were expressed as the mean  the SEM of individual log10
CFU/spleen. The efficacy of the vaccine compared to naive animals was deter-
mined by subtracting the mean CFU/spleen recovered from mice vaccinated with
the nonencapsulated or encapsulated (vjbR::Tn5/alginate, vjbR::Tn5/VpB/core,
or vjbR::Tn5/VpB/shell) vaccine from the mean CFU/spleen recovered from
naive nonvaccinated but challenged mice. The efficacy of the encapsulated vac-
cine compared to the nonencapsulated vaccine was determined by subtracting
the mean CFU/spleen recovered from mice vaccinated with the capsules from
the mean CFU/spleen recovered from mice immunized with the nonencapsu-
lated vaccine.
Statistical procedures. Macrophage infection and survival were expressed as
the mean log CFU  the standard deviation for each group. The intensity of
infection (bacterial clearance and efficacy of vaccine) at each time point was
expressed as the mean log CFU the SEM for each group. Cytokine production
in vitro and in vivo was expressed as mean cytokine concentration the standard
deviation for each group of five mice. Bacterial release from the capsules was
expressed in terms of daily release and plotted versus time. Efficacy studies
compared mice vaccinated with the encapsulated organism and subsequently
challenged mice to mice receiving the nonencapsulated mutant as a vaccine
control that were challenged with wild-type organism. The significance of differ-
ences between vaccinates were analyzed by ANOVA followed by Tukey’s hon-
estly significant difference post test comparing all groups to one another. For
ANOVA, P values of 0.05 were considered statistically significant.
RESULTS
B. melitensis vjbR::Tn5 mutant is highly attenuated for sur-
vival in macrophages and in mice. To assess the vjbR::Tn5
attenuation, J774A.1 macrophages were infected with the mu-
tant and compared to the wild-type B. melitensis 16M. Using a
multiplicity of infection of 100, the ability of the bacteria to
enter and replicate within macrophages was evaluated. Shortly
after infection (t  0 h) there was no difference (P 	 0.05)
between the wild type and the mutant in the number of bac-
teria (three to four per cell) infecting the macrophage (Fig. 1).
In contrast, by 48 h postinfection there was a 2.5-log difference
(P  0.005) in the number of organisms surviving inside the
macrophage (100 per cell for 16M and less than 1 per cell for
the vjbR::Tn5). These results demonstrate that the vjbR::Tn5
mutant has a severely limited capacity to replicate within
J774A.1 macrophages.
To evaluate survival in vivo, BALB/c mice were inoculated
intraperitoneally with 2  106 CFU of B. melitensis vjbR::Tn5
or the 16M parental wild-type strain. Compared to the wild-
type strain 16M, the vjbR::Tn5 mutant was significantly re-
duced by 1.5 to 3.6 logs at all of the time points chosen. There
appears to be a brief period between weeks 1 (P  0.001) and
2 (P 	 0.05) during which the organism replicates and the
numbers of B. melitensis vjbR::Tn5 in the spleen increase, but
by 3 weeks postinoculation the number of organisms in the
spleen exhibits a drastic decline (P  0.001) and drops below
the level of detection by 4 weeks postinfection (P  0.001)
(Fig. 2A). In addition, disruption of vjbR significantly reduced
(P  0.001) splenomegaly at all time points, a finding consis-
tent with the reduction in colonization of the spleen (Fig. 2B).
Evaluation of capsule characteristics. Three different types
of capsules were prepared by using the same basic alginate
formulation. Variations in the formulations included the addi-
tion of VpB to the core or to the shell of the capsule. In
general, the results demonstrate that, despite the differences in
formulations, all of the capsules prepared appeared spherical
and uniform, with a mean diameter of 300 m. To characterize
the bacterial entrapment inside the capsule, B. melitensis 16M
transformed with a GFP-expressing plasmid was encapsulated.
The results revealed the presence of bacteria inside the capsule
(Fig. 3). Furthermore, bacterial viability after encapsulation
exceeded 95%, as demonstrated by recovery of the organism
after dissolution of the capsules. Bacterial release from the
microspheres was monitored in vitro for 40 days. The results
revealed an initial bacterial burst that occurred in the first 2
days, followed by a sustained release that lasted 36 days
(Fig. 4).
Encapsulated B. melitensis vjbR::Tn5 protects against 16M
wild-type challenge. In order to determine the effect of encap-
sulation on immunization, the level of protection provided by
equal numbers of encapsulated and nonencapsulated B.
melitensis vjbR::Tn5 was evaluated against wild-type challenge
at 31 weeks postvaccination. At this time point, nonspecific
activation due to innate immune response to persistent infec-
tion or delayed release of the encapsulated organism had
passed based upon the decrease observed in humoral immunity
and the absence of recovery of the vaccine strain (Fig. 5). At 32
weeks postvaccination (1 week after challenge), all mice, in-
cluding the nonencapsulated group, demonstrated a statisti-
cally significant decrease in bacterial load in the spleen relative
to naive mice, with a 3.14-log reduction (P  0.05) for nonen-
capsulated mutant, a 4.14-log reduction (P  0.005) for BM
vjbR::Tn5 mutant in alginate, a 4.45-log reduction (P  0.001)
for BM vjbR::Tn5 mutant in VpB core, and a 4.98-log reduc-
tion (P  0.001) for BM vjbR::Tn5 mutant in VpB shell com-
pared to naive mice. All groups of mice receiving encapsulated
vaccination exhibited a statistically significant degree of pro-
tection against infection compared to the nonencapsulated
mutant (P  0.001). Among the three encapsulated vaccines,
the BM vjbR::Tn5 mutant with a VpB shell provided the best
FIG. 1. Survival of the B. melitensis vjbR::Tn5 mutant in J774A.1
macrophages. Wild-type strain 16M and the B. melitensis mutant vjbR::
Tn5 were used to infect J774A.1 macrophages at a multiplicity of
infection of 1:100. After 30 min of incubation, followed by 1 h of
treatment with gentamicin, infected macrophages were further incu-
bated for 0 or 48 h. Treated cells were lysed, serially diluted, and plated
on TSA or TSA-kanamycin plates for CFU determination. The values
are the means of three independent experiments  the standard de-
viation. Differences in macrophage colonization by wild-type 16M and
the vjbR::Tn5 mutant were analyzed by Student’s t test (, P 0.005).
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level of protection, increasing the vaccine efficacy by 1.84 logs
(P  0.05) compared to the nonencapsulated vaccine. More-
over, the challenge organism was undetectable in 60% of the
BM vjbR::Tn5 mice (Fig. 6).
Encapsulated BM vjbR::Tn5 elicits vigorous humoral and
cytokine responses. Serum collected at 0, 1, 2, 8, 10, 12, 14, 18,
24, and 30 weeks postvaccination was assayed for the presence
of Brucella-specific antibodies by ELISA. Immunization with
BM vjbR::Tn5 mutant elicited a IgG response that was clearly
detectable at 2 weeks postvaccination for either encapsulated
or nonencapsulated vaccines (Fig. 5). In mice vaccinated with
the nonencapsulated BM vjbR::Tn5 vaccine, IgG levels peaked
at 8 weeks postimmunization, whereas in mice immunized with
BM vjbR::Tn5 with VpB in the shell, the IgG levels increased
steadily and reached a maximum by 18 weeks postimmuniza-
tion. In this case, an induction of higher and sustained antibody
levels correlated with enhanced protection for both BM vjbR::
Tn5 in alginate and vjbR::Tn5 in VpB shell formulations.
To determine the magnitude of the memory response in-
duced by the different vaccine formulations, mice were chal-
lenged at week 31 postvaccination, and the IgG recall response
was evaluated 3 days postchallenge. Animals immunized with
BM vjbR::Tn5/alginate and vjbR::Tn5/VpB/shell underwent a
rapid antibody recall (Fig. 7). The recall responses were stron-
ger for the IgG2a isotype, with a fivefold increase in animals
that received vjbR::Tn5/VpB/shell and a threefold increase in
vjbR::Tn5/alginate vaccinees. Only a modest increase in IgG1
FIG. 2. Kinetics of clearance and spleen weights in BALB/c mice
during B. melitensis vjbR::Tn5 infection. Each BALB/c mouse (n five
animals/time point) was infected with 2  106 CFU of wild-type 16M,
the vjbR::Tn5 mutant or encapsulated vjb::Tn5. (A) At 1, 2, 3, and 4
weeks postinfection, mice were euthanized, and the spleens were as-
sessed for bacterial colonization. The solid line represents the limit of
detection, which is 5 CFU. (B) Spleens from the same mice and at
the same time points were weighed to determine the degree of inflam-
mation conferred by the mutant. For both sets of data, values are the
means  SEM. Differences in colonization or spleen weights were
compared by ANOVA followed by Tukey’s honestly significant differ-
ence posttest to compare all groups to each other. , P  0.05, with a,
b, and c indicating the M16, nonencapsulated vjb::Tn5 mutant, and
encapsulated vjb::Tn5 mutant groups, respectively.
FIG. 3. Fluorescence microscopy image of alginate microspheres
loaded with wild-type 16M. B. melitensis wild-type 16M was trans-
formed with a GFP-expressing plasmid and encapsulated into alginate
microspheres. The bacterial presence inside the capsule and sphere
morphology was assessed via fluorescence microscopy.
FIG. 4. Kinetics of bacterial release in vitro from alginate micro-
capsules. Alginate microbeads were prepared containing 109 CFU of
vjbR::Tn5 mutant/ml, and 1 ml of capsules was resuspended in peptone
saline. Every day, the buffer was completely removed and new peptone
saline was added. Aliquots (100 l) of the buffer were serially diluted
and plated onto TSA-kanamycin plates to determine the number of
bacteria released into the buffer. The solid line represents the limit of
detection, which is 5 CFU.
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(twofold) was observed in the vjbR::Tn5/VpB/shell-immunized
mice (data not shown). In contrast, there was a minimal recall
response in mice vaccinated with the nonencapsulated mutant.
There were no increases in antibody titers in naive but chal-
lenged animals, clearly indicating that the responses observed
here were recall responses rather than an initial priming.
To obtain additional information on the type of immune
response induced by the different BM vjbR::Tn5 capsule for-
mulations at the time of bacterial challenge, the cellular im-
mune response was characterized based on the cytokine secre-
tion in culture supernatants of spleen cells from immunized
mice. All three capsule formulations stimulated elevated levels
of IFN- (P  0.005) and IL-12p70 (P  0.05) (Fig. 8) com-
pared to the nonencapsulated group. All cytokine levels were
statistically significant compared to nonvaccinated animals
(P 0.005). In general, induction of higher Th1 cytokine levels
correlated with the elevated protection exhibited in the encap-
sulated vaccine groups. Spleen cells from all immunized mice
failed to produce IL-4 when stimulated with antigen (data not
shown). No difference in IL-4 responses were detected be-
tween the vaccinated and nonvaccinated animals or between
mice immunized with encapsulated and nonencapsulated for-
mulations. Empty capsules failed to elicit the production of any
of the cytokines measured. The proinflammatory cytokine pro-
file observed after in vitro splenocyte stimulation correlated
with the in vivo cytokine responses of IFN- and IL-12, whose
levels were significantly (P 0.05, P 0.005) higher in animals
vaccinated with encapsulated vaccines (Fig. 9).
DISCUSSION
Efficacious immunization systems to protect against brucel-
losis are needed to overcome the disadvantages of the cur-
rently available vaccines with regard to efficacy in a wide vari-
ety of hosts (28). Second only to immune protection, safety is
FIG. 5. IgG anti-Brucella antibodies in serum from mice immu-
nized with vjbR::Tn5 mutant. BALB/c mice (n  10) were inoculated
intraperitoneally with 105 CFU of either nonencapsulated B. melitensis
vjbR::Tn5 mutant, encapsulated B. melitensis (vjbR::Tn5/alginate), en-
capsulated B. melitensis vjbR::Tn5 with VpB in the core (vjbR::Tn5/
alginate/VpB/core), or encapsulated B. melitensis vjbR::Tn5 mutant
with VpB in the shell (vjbR::Tn5/alginate/VpB/shell). Control groups
received empty capsules or MOPS. At 0, 2, 4, 8, 10, 12, 14, 18, 24, and
30 weeks postvaccination, serum samples were collected and used at a
1:1,000 dilution for IgG determination by ELISA. The results are
shown as means  the standard deviations of the absorbance at A450.
FIG. 6. Immunization efficacy of B. melitensis vjbR::Tn5 vaccine
formulations. BALB/c mice were immunized intraperitoneally with 105
CFU of either nonencapsulated B. melitensis vjbR::Tn5 mutant, encap-
sulated B. melitensis vjbR::Tn5/alginate, encapsulated B. melitensis
vjbR::Tn5 mutant with VpB in the core (vjbR::Tn5/alginate/VpB core),
or encapsulated B. melitensis vjbR::Tn5 mutant with VpB in the shell
(vjbR::Tn5/alginate/VpB shell). Control groups received empty cap-
sules or MOPS. After 31 weeks, mice were challenged intraperitone-
ally with 105 CFU of wild-type 16M. At 1 week postchallenge, mice
were euthanized, spleens were harvested, and the bacterial load was
determined. Values are reported as the log10 recovery of 16M from
spleens, with individual mice in each treatment group represented. The
solid line represents the limit of detection, which is 5 CFU. Differ-
ences in colonization between nonencapsulated and encapsulated
groups were determined by ANOVA followed by Tukey’s honestly
significant difference posttest to compare all groups to each other. *,
P  0.05, and **, P  0.005, with lowercase letters indicating the
groups as follows: a, MOPS group; b, alginate group; c, vjb::Tn5/
alginate group, d, vjb::Tn5/alginate/VpB shell group; e, vjb::Tn5/
alginate/VpB core group; and f, nonencapsulated vjb::Tn5 group.
FIG. 7. IgG2a recall response of B. melitensis vjbR::Tn5 vaccine
formulations. BALB/c mice were immunized intraperitoneally with 105
CFU of either nonencapsulated B. melitensis vjbR::Tn5 mutant, encap-
sulated B. melitensis vjbR::Tn5/alginate mutant, encapsulated B.
melitensis vjbR::Tn5 mutant with VpB in the core (vjbR::Tn5/alginate/
VpB/core), or encapsulated B. melitensis vjbR::Tn5 mutant with VpB in
the shell (vjbR::Tn5/alginate/VpB/shell). Control groups received
empty capsules or MOPS. After 31 weeks, mice were challenged in-
traperitoneally with 105 CFU wild-type 16M. At 3 days postchallenge
mice were bled, and IgG2a titers were determined by ELISA. Differ-
ences in responses between the nonencapsulated and the encapsulated
groups were determined by Student’s t test, comparing the changes in
antibody titer on the day of challenge to that at 3 days postchallenge
for each individual treatment group (*, P  0.05).
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of critical importance for ideal live Brucella vaccines. The ab-
sence of virulence in the target host and in humans will help to
avoid virulence-related sequelae. Increasing knowledge of vir-
ulence factors and Brucella pathogenesis mechanisms provide
us with the tools to construct new attenuated strains. Previous
studies in our laboratory using transposon-based mutagenesis
strategies have identified genes related to survival and viru-
lence (16, 36). Among the genes identified, vjbR::Tn5 mutants
were evaluated for survival in macrophages and the mouse
model to confirm attenuation and immune potential. As shown
in the present study, BM vjbR::Tn5 was defective for survival
within macrophages and rapidly cleared from the spleen in
BALB/c mice. In mice, the mutant was significantly reduced in
number by 1 week postinfection and was completely cleared by
4 weeks. In contrast, 16M persists in the mouse spleen for
more than 16 weeks (17). vjbR::Tn5 safety was further revealed
by the absence of splenomegaly in inoculated mice. Even at 2
weeks, when the bacterial load in the spleen was high, the
FIG. 8. Production of cytokines in stimulated spleen cells from
vjbR::Tn5-vaccinated BALB/c mice. Mice were vaccinated with 105
CFU of either nonencapsulated B. melitensis vjbR::Tn5 mutant, encap-
sulated B. melitensis vjbR::Tn5/alginate mutant, encapsulated B.
melitensis vjbR::Tn5 mutant with VpB in the core (vjbR::Tn5/alginate/
VpBcore), or encapsulated B. melitensis vjbR::Tn5 mutant with VpB in
the shell (vjbR::Tn5/alginate/VpBshell). Control groups received
empty capsules or MOPS. At 31 weeks postvaccination, mice were
euthanized, and splenocytes were harvested and stimulated with heat-
inactivated B. melitensis 16M or medium alone as a control. IFN-
(A) and IL-12p70 (B) production (pg/ml) was detected after 72 h of
stimulation by using a multiplex suspension array system (Bioplex).
Cytokine production was expressed as the mean cytokine concentra-
tion  SEM for each group of mice. Differences in colonization be-
tween the nonencapsulated and encapsulated groups were determined
by ANOVA followed by Tukey’s honestly significant difference post-
test comparing all groups to each other. *, P  0.05, and **, P  0.01,
with lowercase letters indicating the groups as follows: a, MOPS group;
b, alginate group; c, vjb::Tn5/alginate group, d, vjb::Tn5/alginate/VpB
shell group; e, vjb::Tn5/alginate/VpB core group; and f, nonencapsu-
lated vjb::Tn5 group.
FIG. 9. Cytokine production in the sera of BALB/c mice immu-
nized with the vjbR::Tn5 mutant. Mice were vaccinated with 105 CFU of
either nonencapsulated B. melitensis vjbR::Tn5 mutant, encapsulated B.
melitensis vjbR::Tn5/alginate mutant, encapsulated B. melitensis vjbR::
Tn5 mutant with VpB in the core (vjbR::Tn5/alginate/VpBcore), or
encapsulated B. melitensis vjbR::Tn5 mutant with VpB in the shell
(vjbR::Tn5/alginate/VpBshell). Control groups received empty cap-
sules or MOPS. Mice were bled at 0, 10, and 30 weeks postvaccination.
IFN- (A) or IL-12 (B) determination from the serum was performed
by ELISA. The results are represented as the mean cytokine concen-
tration  SEM for each group of mice. Differences in colonization
between the nonencapsulated and encapsulated groups were deter-
mined by ANOVA followed by Tukey’s honestly significant difference
posttest comparing all groups to each other. *, P  0.05, and **, P 
0.01, with lowercase letters indicating the groups as follows: a, MOPS
group; b, alginate group; c, vjb::Tn5/alginate group, d, vjb::Tn5/
alginate/VpB shell group; e, vjb::Tn5/alginate/VpB core group; and f,
nonencapsulated vjb::Tn5 group.
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mean spleen weights in BM vjbR::Tn5-inoculated mice was 110
mg versus 653 mg for 16M (Fig. 2B). The currently available
vaccine strains S19 and Rev-1 induce splenomegaly in mice,
totally undesirable side effects for human vaccination (29).
Differences in survival and inflammatory response exhibited by
vjbR::Tn5 provide an opportunity to evaluate its use as an
improved vaccine candidate for possible human use.
Recent data suggest that the manner in which antigen
reaches the lymph organs and how it is delivered to the anti-
gen-presenting cells is fundamental in the induction of an
optimal immune response (11). There is experimental evi-
dence to support the observation that microencapsulation
serves to modify the uptake and processing of the antigen (11,
30). Based on these observations, we developed a controlled
release strategy using highly attenuated mutants. Alginate-
VpB microspheres permit a constant or pulsed release of en-
capsulated organism, simulating continuous exposure, that
might potentiate the vaccine efficacy. Release from alginate
matrices generally occurs by diffusion through pores of the
capsule or by erosion of the polymer network (35). In the case
of standard bacterial entrapment methods used for Mycobac-
terium bovis BCG or bifidobacteria, cells escape through ero-
sion rather than diffusion due to bacterial size and surface
charge (2, 9). VpB was added to the formulation in an attempt
to extend the time frame over which the capsule dissolution
occurs, due to the characteristic resistance of the protein to
enzymatic breakdown (34).
During microsphere formulation microorganisms were ex-
posed to relatively mild conditions that did not cause signifi-
cant bacterial death; this approach permits the development of
live encapsulated vaccines in contrast to previously published
encapsulation procedures in which the viability of the bacteria
is compromised due to the extreme conditions, including ul-
trasound homogenization, direct exposure to organic solvents,
and shear stress (19). The use of a GFP plasmid-transformed
organism helped to confirm bacterial entrapment inside the
capsules and demonstrated uniform spherical capsule forma-
tion. This morphology was maintained even with the inclusion
of VpB, which enhances capsule stability via cross-linking due
to its high lysine and arginine content when substituted for
poly-L-lysine (26, 34).
Protection studies against wild-type challenge with both
nonencapsulated and encapsulated organisms protected mice
significantly, but the vaccine efficacy was increased substan-
tially when the mutant was delivered in an encapsulated form.
The addition of VpB in the core or shell of the capsule further
enhanced protection. VpB is a protease-resistant protein from
Fasciola hepatica that retards capsule erosion and extends the
release profile. Encapsulation and incorporation of VpB in
vaccine formulations is one approach to improving immuniza-
tion efficacy for Brucella and other organisms.
The degree of protection conferred by the different vaccine
formulations was evaluated via antibody response. Immuniza-
tion with B. melitensis vjbR::Tn5 mutant in microcapsules in-
duced prolonged elevation of total IgG levels compared to
the nonencapsulated vaccine, as predicted for our controlled
release format. Vaccination efficacy relies on the effective
generation and maintenance of immunological memory. After
challenge, encapsulated vjbR::Tn5/alginate/VpB/shell and vjbR::
Tn5/alginate induced anti-Brucella IgG levels within 3 days;
such a quick response can be attributed to the generation of an
immunological memory response by the vaccine. Isotype anal-
ysis revealed a correlation between elevated IgG2a antibody
titers with higher IL-12 responses, suggesting the induction of
a Th1 cell-mediated response. These results strongly suggest
the induction of a protective immune response against intra-
cellular pathogens, enhanced by encapsulation and controlled
release. Future experiments are designed to distinguish be-
tween increased antibody avidity and recognition of additional
antigenic epitopes.
Published reports have shown that spleen cells from mice
previously inoculated with live vaccines induced a Th1 type
response to Brucella antigens in vitro, while splenocytes from
mice immunized with killed vaccines induced Th2 responses
(37). Moreover, it has been clearly established that IFN- is an
important component of the Th1 response, activating macro-
phages for increased microbial killing (5, 15, 23). Studies per-
formed with highly attenuated Brucella mutants indicate that
both nonencapsulated and encapsulated vaccine induced
higher IFN- levels than were observed in naive mice; how-
ever, encapsulation increased IFN- levels threefold over non-
capsulated, suggesting a strong potentiation of the protective
immune response induced through controlled release. This is
consistent with in vitro results indicating continuous release of
the organism for up to 35 days (Fig. 4), suggesting continuous
boosting of the host immune system with antigen. In addition,
higher cytokine concentrations coincided with the increased
levels of protection generated by encapsulation. These data
were corroborated by cytokine analysis of serum samples.
Although IFN- is critical for activating macrophages, other
cytokines also play an important role in controlling Brucella.
IL-12, a Th1-type cytokine mainly produced by macrophages,
promotes IFN- production by T cells that induce murine B
cells to switch to an IgG2a isotype (13). It also induces differ-
entiation of CD4 Th1 cells (31). In this vaccination trial, IL-12
was also produced in significant levels compared to naive mice.
Two of the three groups of animals that received microcap-
sules (vjbR::Tn5/alginate and vjbR::Tn5/alginate/VpB/shell)
produced statistically significant levels compared to the non-
encapsulated vaccine, suggesting that IL-12 plays an important
role. One alternative may be that elevated IL-12 levels influ-
ence the development of antibody-mediated protective immu-
nity, contributing to the clearance of the infection (12, 13, 21).
Isotype analysis confirmed the correlation between elevated
IgG2a antibody titers with the higher IL-12 responses (14).
It is important to mention that the microcapsules alone are
insufficient to provoke the secretion of cytokines in cell culture
supernatants. Furthermore, statistically significant concentra-
tions of any cytokine were not detected in mice vaccinated with
empty capsules, suggesting that the booster effect generated by
the three capsule formulations was due to a continuous pre-
sentation of antigen. Experiments in progress are designed to
further characterize the basis for this response.
In the present study, mice were vaccinated with a single dose
of an attenuated Brucella mutant for 31 weeks. Previous stud-
ies have not analyzed vaccine candidate performance at such
late time points. We chose the 6-month time point to rule out
the action of the innate immunity due to the presence of the
organism (because of the sustained release of the mutant from
the capsule) to better asses the quality of the memory response
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generated by the different vaccine formulations delivered as a
single dose. No vaccine strain was detectable at the time of
challenge.
In summary, our findings suggest that encapsulation of live
Brucella provides enhancement of vaccine efficacy. Adequate
priming of the immune system is of extreme importance in
determining the quality of a memory response. We were able
to achieve this by encapsulation of the organism in a single
dose, which is ideal for patient compliance. The vjbR::Tn5
mutant is a suitable vaccine candidate that warrants further
investigation based upon its reduced virulence in macrophages
and BALB/c mice and its ability to generate protection in the
mouse model. We were able to demonstrate a specific Th1
response that did improve when the vaccine was given using a
controlled release vehicle. Further studies are planned to gen-
erate a deletion mutant to avoid the use of vaccine strains with
antibiotic resistance genes and to rule out the possibility of
reversion to virulence. Experiments under way are designed to
elucidate the role of capsules in antigen presentation.
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